content_image/281428.jpg
Astellas expects to make a greater contribution to the treatment of type 2 diabetes. In Japan, Astellas will co- promote Suglat with Kotobuki and MSD K.K. 

## Other New Products 

Besides the aforementioned mainstay products, quite a few new products were launched in fiscal 2013, including the functional dyspepsia treatment Acofide (on sale from June 2013), the transdermal hypertension medication Bisono Tape, (on sale from September 2013), and the diarrhea- predominant irritable bowel syndrome treatment Irribow OD Tablets (on sale from January 2014). 

## Other Mainstay Products 

Sales of the Lipitor product line, Gaster, Myslee and Seroquel in fiscal 2013 were as follows. Sales of each of these prod- ucts declined due primarily to the impact of generic drugs. 

Sales of the Lipitor product line (hypercholesterolemia treatment), which includes Caduet (combination drug con- taining Lipitor and a long-acting calcium antagonist), declined by 11.6%, to ¥62.4 billion. In fiscal 2013, the market for statins in Japan shrank 1.4% year on year to approximately ¥264.0 billion. 

Sales of Gaster (treatment for peptic ulcers and gastritis) declined 14.9% to ¥25.7 billion. In fiscal 2013, the peptic ulcer and gastritis market for H2 receptor antagonists and proton pump inhibitors expanded 1.9% to approximately ¥320.0 billion. 

Sales of Myslee (insomnia treatment) decreased 12.6% to ¥28.2 billion. In fiscal 2013, the market for drugs to treat insomnia in Japan shrank 0.9% year on year, to approxi- mately ¥80.0 billion. 

Sales of Seroquel (schizophrenia treatment) decreased 31.2% to ¥19.6 billion. The Japanese market for anti- schizophrenic agents showed growth of 4.7% to approximately ¥171.0 billion in fiscal 2013. 

## Americas 

## Adenoscan/Lexiscan (Pharmacologic stress agent) 

Total sales of Adenoscan and Lexiscan in the U.S. declined by 3.5% to US$617 million on a U.S. dollar basis, mainly due to the launch in September 2013 of generic products for Adenoscan in the U.S. Lexiscan continued to show growth, rising 2.2% to US$585 million. Total sales increased 16.5% to ¥61.8 billion when converted to yen. 

## Tarceva (Lung and pancreatic cancer treatment) 

Tarceva-related revenues increased 1.4% to US$446 mil- lion on a U.S. dollar basis. When converted to yen, sales increased 22.3%, to ¥44.7 billion. 

In the U.S., we have been co-promoting Tarceva with Genentech, Inc., with earnings split equally between both companies. We also have a license agreement with F. Hoffmann-La Roche Ltd in other countries, and receive royalties based on sales. These revenues are recorded as sales in the Americas. 

Furthermore, in the U.S., approval was obtained in May 2013 for the additional indication of the first-line treatment for people with metastatic non-small cell lung cancer whose tumors have certain epidermal growth factor receptor (EGFR) activating mutations as detected by an FDA-approved test. 

## Cost of Sales, Gross Profit 

Cost of sales increased by ¥21.9 billion to ¥330.6 billion. The cost of sales ratio fell 2.4 percentage points in fiscal 2013, to 29.0%, mainly due to changes in the product mix. 

Gross profit increased by ¥136.1 billion, or 20.2%, to ¥809.3 billion, due to growing sales, as well as a decrease in the cost of sales ratio. 

<img src='content_image/281428.jpg'>

